<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010646</url>
  </required_header>
  <id_info>
    <org_study_id>2009-015121-37</org_study_id>
    <secondary_id>ANRS HC 23 COAT-IFN</secondary_id>
    <nct_id>NCT01010646</nct_id>
  </id_info>
  <brief_title>Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4</brief_title>
  <acronym>COAT IFN</acronym>
  <official_title>Multicentre, Randomised, Open-label Study Comparing the Tolerability and Viral Reduction of the Combination of IFN Alpha-2b XL + Ribavirin Versus Peg IFN Alpha-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Flamel Technologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three-parallel-arm, open-label, international (France and Romania) study, comparing three
      treatments

      The purpose of this study is to confirm if IFN alfa-2b XL has a better antiviral activity and
      tolerability as compared with current marketed reference, while combined with ribavirin, in a
      3-month therapy setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interferon alfa-2b XL (IFN alfa-2b XL) is a novel sustained release interferon α-2b drug
      product that is being developed by FLAMEL TECHNOLOGIES using its Medusa® technology, aiming
      at reducing the toxicity and enhancing the biological response. In the present study,
      patients will be randomly assigned to either IFN alfa-2b XL 27 MUI, IFN alfa-2b XL 36 MUI, or
      IFN peg alfa-2b 1.5 µg/kg, all administered once a week for 12 weeks by subcutaneous
      injections, in combination with weight dosed ribavirin daily administered orally in two
      divided doses. Doses will be adapted according to the dose modification guidelines for
      combination therapy labelled in the ribavirin prescribing information.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load decrease at Week 4 and Week 12 of treatment with IFN alfa-2b XL 27 MIU, IFN alfa-2b XL 36 MIU and the marketed reference product (PEG IFN alfa-2b 1.5μg/kg) in combination with ribavirin</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with early virologic response (EVR) (reduction of at least 2 log viral load) at the end of week 12</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with complete early virologic response (EVR) (viral load &lt;15 IU) at the end of the week 12</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>GP1N IFN alfa-2bXL 27 MUI + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN alfa-2bXL 27 MUI, powder and solvent for solution injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP2N IFN alfa-2b XL 36 MUI + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN alfa-2b XL 36 MUI, powder and solvent for solution injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP3N IFN peg alfa-2b 1.5 µg/kg + Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IFN peg alfa-2b 1.5 µg/kg,administered once a week for 12 weeks by subcutaneous injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN alfa-2b XL 27 MUI + Ribavirin</intervention_name>
    <description>IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses</description>
    <arm_group_label>GP1N IFN alfa-2bXL 27 MUI + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN alfa-2b XL 36 MUI + Ribavirin</intervention_name>
    <description>IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses</description>
    <arm_group_label>GP2N IFN alfa-2b XL 36 MUI + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN peg alfa-2b 1.5 µg/kg + Ribavirin</intervention_name>
    <description>IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses</description>
    <arm_group_label>GP3N IFN peg alfa-2b 1.5 µg/kg + Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient having voluntarily signed the Informed Consent Form prior to any study
             specific procedure being performed

          -  Male or female HCV genotype 1 or 4 infected patients (positive serum HCV RNA), aged
             between 18 and 65 years inclusive, with a body mass within the range over or equal of
             45Kg and below or equal to 100 Kg

          -  Patient being either naïve to therapy, either non-responder to previous standard
             Peg-interferon α + ribavirin therapy,

          -  With no absolute contra-indication to interferon α or ribavirin

          -  Female patients must be non-lactating and of non-childbearing potential, or have a
             negative pregnancy test results to enter the study

          -  No evidence of acute or advanced liver disease, uncontrolled diabetes, cardiovascular,
             immunological, or thyroid disease, and no recently diagnosed malignancy

          -  Vital signs within normal ranges, or if outside the normal ranges, not deemed
             clinically significant in the opinion of the Investigator. An ECG with no clinically
             significant abnormalities

        Exclusion Criteria:

          -  History of solid organ transplantation

          -  Severe systemic infection, uncontrolled diabetes, cancers, associated liver disease

          -  General anesthesia or recent blood transfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian TREPO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de la Croix Rousse, Service d'Hépato-Gastro-Entérologie, 69004 Lyon - FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
    <description>French National Agency for Research on AIDS and Viral Hepatitis website</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>viral kinetics</keyword>
  <keyword>antiviral response</keyword>
  <keyword>Genotype 1 or 4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

